| Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. IF Tannock, D Osoba, MR Stockler, DS Ernst, AJ Neville, MJ Moore, ... Journal of clinical oncology 14 (6), 1756-1764, 1996 | 2074 | 1996 |
| Enzalutamide with standard first-line therapy in metastatic prostate cancer ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ... New England Journal of Medicine 381 (2), 121-131, 2019 | 1446 | 2019 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 827 | 2021 |
| The importance of patient-reported outcomes in clinical trials and strategies for future optimization R Mercieca-Bebber, MT King, MJ Calvert, MR Stockler, M Friedlander Patient related outcome measures, 353-367, 2018 | 550 | 2018 |
| Bisphosphonates and other bone agents for breast cancer B O'Carrigan, MHF Wong, ML Willson, MR Stockler, N Pavlakis, ... Cochrane database of systematic reviews, 2017 | 525 | 2017 |
| Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III … NC Tebbutt, K Wilson, VJ Gebski, MM Cummins, D Zannino, ... Journal of Clinical Oncology 28 (19), 3191-3198, 2010 | 522 | 2010 |
| Bisphosphonates for breast cancer N Pavlakis, RL Schmidt, MR Stockler Cochrane Database of Systematic Reviews, 2005 | 492 | 2005 |
| Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials A Gennari, M Stockler, M Puntoni, M Sormani, O Nanni, D Amadori, ... Journal of clinical oncology 29 (16), 2144-2149, 2011 | 271 | 2011 |
| Duration of chemotherapy for advanced non–small-cell lung cancer: a systematic review and meta-analysis of randomized trials YY Soon, MR Stockler, LM Askie, MJ Boyer Journal of clinical oncology 27 (20), 3277-3283, 2009 | 267 | 2009 |
| Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer M Stockler, NRC Wilcken, D Ghersi, RJ Simes Cancer treatment reviews 26 (3), 151-168, 2000 | 253 | 2000 |
| Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 … GM Duchesne, HH Woo, JK Bassett, SJ Bowe, C D'Este, M Frydenberg, ... The Lancet Oncology 17 (6), 727-737, 2016 | 246 | 2016 |
| Third consensus on medical treatment of metastatic breast cancer S Beslija, J Bonneterre, HJ Burstein, V Cocquyt, M Gnant, V Heinemann, ... Annals of oncology 20 (11), 1771-1785, 2009 | 243 | 2009 |
| Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer MR Stockler, F Hilpert, M Friedlander, MT King, L Wenzel, CK Lee, F Joly, ... Journal of Clinical Oncology 32 (13), 1309-1316, 2014 | 215 | 2014 |
| Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer P Glare, G Pereira, LJ Kristjanson, M Stockler, M Tattersall Supportive Care in Cancer 12, 432-440, 2004 | 196 | 2004 |
| Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer MR Stockler, VJ Harvey, PA Francis, MJ Byrne, SP Ackland, B Fitzharris, ... Journal of clinical oncology 29 (34), 4498-4504, 2011 | 193 | 2011 |
| Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 … D Stark, M Nankivell, E Pujade-Lauraine, G Kristensen, L Elit, M Stockler, ... The lancet oncology 14 (3), 236-243, 2013 | 192 | 2013 |
| Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review CA Hauser, MR Stockler, MHN Tattersall Supportive Care in Cancer 14, 999-1011, 2006 | 180 | 2006 |
| Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in AK Nowak, WJ Lesterhuis, PS Kok, C Brown, BGM Hughes, DJ Karikios, ... The Lancet Oncology 21 (9), 1213-1223, 2020 | 170 | 2020 |
| PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP … JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ... The Lancet Oncology 23 (11), 1389-1397, 2022 | 169 | 2022 |
| Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo … M Stockler, J Vardy, A Pillai, D Warr Journal of clinical oncology 22 (16), 3389-3394, 2004 | 169 | 2004 |
Val GebskiNHMRC Clinical TRials Centre, University of SydneyПотвърден имейл адрес: ctc.usyd.edu.au
